532 related articles for article (PubMed ID: 30025280)
41. [Expression level of Wilms' tumor 1 gene and its correlation with clinical features in patients with myeloproliferative neoplasms].
Liu C; Wu SY; Zhang AB; Luo P; Zhou Y; Liu Y; Zuo XL
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3658-3664. PubMed ID: 38018065
[No Abstract] [Full Text] [Related]
42. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
Mesa RA; Passamonti F
Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
[TBL] [Abstract][Full Text] [Related]
43. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
44. Novel therapeutics in myeloproliferative neoplasms.
Venugopal S; Mascarenhas J
J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
[TBL] [Abstract][Full Text] [Related]
45. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
46. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
47. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
Yan J; Ding YW; Wang PY; Wu YP; Zhang HC; Liu LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1540-1547. PubMed ID: 34627437
[TBL] [Abstract][Full Text] [Related]
48. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
50. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
[TBL] [Abstract][Full Text] [Related]
51. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
52. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.
Kreft A; Kindler T; Springer E; Kirkpatrick CJ
Virchows Arch; 2011 Nov; 459(5):521-7. PubMed ID: 22006129
[TBL] [Abstract][Full Text] [Related]
53. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
54. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
55. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
56. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.
Lucia E; Martino B; Mammi C; Vigna E; Mazzone C; Gentile M; Qualtieri G; Bisconte MG; Naccarato M; Gentile C; Laganà C; Romeo F; Neri A; Nobile F; Morabito F
Leuk Lymphoma; 2008 Oct; 49(10):1907-15. PubMed ID: 18720212
[TBL] [Abstract][Full Text] [Related]
57. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
58. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Bose P; Verstovsek S
J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
[TBL] [Abstract][Full Text] [Related]
59. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Stetka J; Usart M; Kubovcakova L; Rai S; Rao TN; Sutter J; Hao-Shen H; Dirnhofer S; Geier F; Bader MS; Passweg JR; Manolova V; Dürrenberger F; Ahmed N; Schroeder T; Ganz T; Nemeth E; Silvestri L; Nai A; Camaschella C; Skoda RC
Blood; 2023 Apr; 141(17):2127-2140. PubMed ID: 36758212
[TBL] [Abstract][Full Text] [Related]
60. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]